ARTICLE | Company News
Ambrilia, SurModics deal
February 22, 2010 8:00 AM UTC
SurModics terminated a 2001 deal to develop and commercialize a sustained release formulation of octreotide claiming Ambrilia is in breach of contract. Ambrilia has denied the allegation. Further deta...